Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by stockbuphoonon Feb 17, 2022 7:36pm
125 Views
Post# 34440201

RE:Stockbuphoon

RE:Stockbuphoon

Yes, that is an interesting thought that Boehringher should just pounce now but I would imagine that thomvest would not sell and they own the majority. It would drive price up a bit but they couldn't get control from thomvest. The deal on the table was real in 2018 and valuations in  2018 of $10 by a very well respected US Investment Bank are real as well.

Steve33 wrote:
The companies that know the clinical data on the 4050 pbi indications that almost made a supposed deal with Pierre could buy Liminal for next to nothing getting their cash and small molecule assets. That would be extremely cheap and probably the best steal ever. That is if the Alstom trial was legit.

 

<< Previous
Bullboard Posts
Next >>